吸入激素联合口服缓释茶碱控制中度持续哮喘的观察  

Effect of budesonide and doxofylline on patients with moderate persistent asthma

作　　者：陈卓昌[1] 丁娟娟[2] 钱皓瑜[2] 林香花[2] 冯可青[2] 王静[1] 

机构地区：[1]郑州大学第一附属医院呼吸与危重症医学科,450000 [2]郑州大学人民医院呼吸与危重症医学科

出　　处：《实用医学杂志》2014年第24期4015-4017,共3页The Journal of Practical Medicine

基　　金：河南省医疗卫生专项基金(编号:1020124)

摘　　要：目的:观察吸入激素联合缓释茶碱对中度持续哮喘患者的治疗作用。方法:中度哮喘患者60例,随机分为试验组30例和对照组30例。试验组患者每日吸入普米克都保,每吸200μg,每日2次;口服多索茶碱片0.2每日2次。对照组患者每日吸入布地奈德/福莫特罗每吸160/4.5μg,每日2吸。疗程3个月。比较治疗前后Fe NO、痰嗜酸粒细胞计数、PEF、ACT评分等指标的变化,并与对照组相比较,评估该方案的临床使用价值。结果:治疗1个月时,试验组在改善PEF、ACT评分方面,明显不及对照组(均P<0.05),痰嗜酸粒细胞比例的改善优于对照组(P<0.05),Fe NO无明显区别(P>0.05);治疗3个月时,试验组对痰嗜酸粒细胞比例的改善优于对照组(P<0.05),对Fe NO、PEF、ACT评分的改善与对照组无明显区别(均P>0.05)。结论:布地奈德/多索茶碱与布地奈德/福莫特罗控制哮喘的效果无明显区别。Objective To observe the effect of budesonide/doxofylline on patients with persistent asthma. Methods Sixty patients with moderate asthma were randomly divided into treatment group and control group. Pati ents in treatment group accepted the inhalation budesonide 400 μg/d and doxofylline tablet 0.2 bid po but those in control group accepted the inhalation budesonide/formoterol 160/4.5μg bid. FeNO, sputum eosinophils, PEF and ACT scores were compared between two groups. Results PEF and ACT scores in treatment group were lower to tho., e in control group （P 〈 0.05）, whereas the score of sputum eosinophils in treatment group was higher （P 〈 0.05） one month later. There was no significant difference in FeNO between two groups （P 〉 0.05）. After three months, spt tum eosinophils in treatment group were better than that in control group （P 〈 0.05）, whereas there was no signifi cant difference in PEF, ACT scores and FeNO between two groups （P 〉 0.05）. Conclusion There is no significant differ, race in controlling asthma between budesonide/doxofylline and budesonide/formooterol

关 键 词：哮喘 多索茶碱 布地奈德 

分 类 号：R562.25[医药卫生—呼吸系统]